A method for separating anti-inflammatory active ingredients of black wolfberry and application of the active ingredients in anti-inflammatory products

A method for isolating anti-inflammatory components from black wolfberry using chromatography and HPLC identifies 5-hydroxymethylfurfural, demonstrating efficacy in reducing key inflammatory markers, addressing the gap in existing research on black wolfberry components beyond anthocyanins.

CN114957172BActive Publication Date: 2024-12-03NORTHWEST INST OF PLATEAU BIOLOGY CHINESE ACAD OF SCI
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202210475348.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-29
Publication Date
2024-12-03
Estimated Expiration
2042-04-29

AI Technical Summary

Technical Problem

Current pharmacodynamics research on black wolfberry primarily focuses on anthocyanins, neglecting the potential anti-inflammatory effects of other components, necessitating a method for simple and effective separation of these active components for broader therapeutic applications.

Method used

A method involving alcohol extraction, polyamide powder mixing, MCI and macroporous chromatography, and high-performance liquid chromatography to isolate anti-inflammatory components Fr1 and Fr1-2 from black wolfberry, identified as 5-hydroxymethylfurfural, which are used in anti-inflammatory products.

Benefits of technology

The isolated components demonstrate significant anti-inflammatory activity by reducing the expression of inflammatory factors TNF-α, IL-1β, IL-6, COX-2, and p-IκBα/IκBα proteins, providing a basis for further research and development of anti-inflammatory products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114957172B_ABST
    Figure CN114957172B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of separation of plant active components, and relates to a method for separating anti-inflammatory active components of black wolfberry fruit. At present, the pharmacodynamics research on black wolfberry mainly focuses on anthocyanins, and no reports have been seen on the efficacy research of other components. Therefore, screening and separating the anti-inflammatory active components of black wolfberry are of great significance for preventing and treating various diseases caused by inflammation. The present invention is achieved by the following technical scheme: 1) taking the alcohol extract of black wolfberry fruit and mixing it with polyamide powder; 2) separating the above mixed powder through an MCI open chromatographic column to obtain components Fr1, Fr2, and Fr3; 3) separating component Fr1 after removing sugar from a macroporous resin column to obtain components Fr1-1 and Fr1-2. By establishing an LPS-induced RAW264.7 cell inflammation model, the obtained components are screened for anti-inflammatory activity, and it is found that the active site Fr1-2 in the black wolfberry fruit has a good anti-inflammatory effect. The present invention provides a new method for separating anti-inflammatory components in black wolfberry fruit.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of separation of plant active components and relates to a method for separating anti-inflammatory active components of black wolfberry. Background Art

[0002] Lycium ruthenicum Murr., also known as "Qionoying-Halmag" in Mongolian medicine and "Pangma" in Tibetan medicine, is a perennial multi-branched thorny shrub of the Lycium genus (Lycium L.) of the Solanaceae family, named after its black fruit. Lycium ruthenicum Murr. is resistant to salt and alkali, high temperature and drought, and is a medicinal plant unique to the northwest desert region of my country. It is currently mainly distributed in Xinjiang, Qinghai, Ningxia, Gansu, northern Shaanxi and Inner Mongolia in my country, and is also distributed in Central Asia, the Caucasus and Europe. Classic Tibetan medicine works such as "Four Medical Classics" and "Jingzhu Materia Medica" record that black wolfberry is often used to treat heart heat disease, irregular menstruation, heart disease, amenorrhea, etc., and is used as a tonic and blood pressure lowering medicine in the folk. "Uyghur Medicine Records" records that the fruit and root bark of black wolfberry have certain therapeutic effects on urethral stones, skin diseases, gingival bleeding, etc. It is used as a tonic and strengthening medicine in the folk. Black wolfberry is rich in anthocyanins, flavonoids, polysaccharides, alkaloids and other chemical components.

[0003] Inflammation refers to a defensive effect produced by the living tissue of the system itself against external inflammatory factors after the body is stimulated by the outside world. It is the result of the interaction between inflammatory mediators and transcription factors. Inflammatory response is a common clinical pathological process that can occur in tissues and organs in various parts of the body. Inflammation is closely related to many diseases, such as diabetes, Alzheimer's disease, arthritis, etc., which seriously threaten people's health. Modern pharmacological studies have shown that black wolfberry has biological activities such as antioxidant, cardiovascular protection, and liver protection. Studies have found that black wolfberry anthocyanin extract can play a neuroprotective role by inhibiting neuroinflammation and other pathways. Patent CN 113995798 A shows that black wolfberry anthocyanin extract can significantly inhibit acute gouty arthritis caused by sodium urate crystals. The above studies show that black wolfberry has a good anti-inflammatory effect. However, the current pharmacodynamics research on black wolfberry mainly focuses on anthocyanins, and no reports have been reported on the efficacy of other components. Therefore, screening and separating the anti-inflammatory active components of black wolfberry are of great significance for the prevention and treatment of various diseases caused by inflammation. Summary of the invention

[0004] In view of this, the object of the present invention is to provide a method for separating the anti-inflammatory active components of Lycium ruthenicum, which has the characteristics of simple operation and easy separation.

[0005] At the same time, the purpose of the present invention is also to use the active components of black wolfberry separated by the above separation method in anti-inflammatory or Gram-negative bacteria inhibition products to provide a basis for further research on the anti-inflammatory effect of black wolfberry.

[0006] A method for separating anti-inflammatory active components of ruthenic wolfberry, comprising the following contents:

[0007] 1) taking an alcohol extract of Lycium ruthenicum fruit and mixing it with polyamide powder;

[0008] 2) Separating the mixed powder through an MCI open chromatography column to obtain components Fr1, Fr2, and Fr3;

[0009] The method used is liquid chromatography, using a three-phase system of water A / methanol B / dichloromethane C as an eluent, and the elution conditions are: 0-120 min, 100% A-100% B; 120-180 min, 100% B-100% C; 120-180 min, 100% B isocratic; 180-210 min, 100% A isocratic;

[0010] 3) Separating the component Fr1 through a macroporous chromatography column to obtain components Fr1-1 and Fr1-2;

[0011] The separation column used was a D101 macroporous resin column, and the chromatographic conditions were: mobile phase: A: water B:

[0012] Methanol, 0-30 min: 0% B; 30-90 min: 0-50% B; 90-120 min: 50% B.

[0013] In the technical solution of the present invention, the component Fr1-2 is further separated by liquid chromatography to obtain compound 1, wherein the mobile phase is: A: water B: methanol; the chromatographic conditions are: 0-30min: 5%-20% B.

[0014] Furthermore, the present invention uses high performance liquid chromatography to analyze and identify compound 1.

[0015] Furthermore, the detection conditions were as follows: detection column C18 (kromasil 100-5-C18, 4.6×250 mm, M05CLA25 / E171498), mobile phase A: water, mobile phase B: methanol; elution conditions: 0-30 min, 5-20% B gradient elution; flow rate: 1 mL·min -1 ; Column temperature 30℃; Detection wavelength: 280nm.

[0016] The structural formula of compound 1 obtained by separation and identification using the above method is:

[0017] In the technical solution of the present invention, the alcohol extract of wolfberry fruit refers to the extract of wolfberry extracted with methanol, and the extraction method thereof includes but is not limited to conventional extraction methods such as leaching, hot reflux, and ultrasonic extraction.

[0018] In a specific embodiment of the present invention, an leaching method is used to extract the anti-inflammatory active ingredients in black wolfberry, and the extraction conditions are a liquid-to-solid ratio of 10 to 30 mL g -1 , extract 1 to 5 times, each time for 4-5 days. After each extraction, filter the extract, protect from light and reduce pressure to obtain the alcohol extract of black wolfberry fruit.

[0019] Furthermore, the above-mentioned wolfberry fruit alcohol extract is mixed with polyamide powder, and then dried, ground and sieved.

[0020] Furthermore, the drying temperature is 30-50° C., and the sieve size used is 10-30 meshes.

[0021] In the technical solution of the present invention, the flow rate of the liquid chromatography in step 2) is 50 mL min -1 , the detection wavelength is 210nm;

[0022] Furthermore, in step 3), the liquid chromatography flow rate is 40 mL min -1 ; The detection wavelengths of components Fr1-1 and Fr1-2 are 210nm and 280nm respectively.

[0023] In the technical solution of the present invention, the specification of the D101 macroporous resin column in step 3) is 49×460 mm.

[0024] The present invention detected the effects of various components in the extract of Lycium ruthenicum fruit on the cell viability, NO release and expression level of inflammatory factors in the RAW264.7 cell inflammation model induced by LPS. The results showed that the active components Fr1 and Fr1-2 had good anti-inflammatory effects. When the concentration of Fr1 was 25 μg·mL -1 The expression level of inflammatory factor TNF-α can be significantly reduced when the concentration is 50 μg·mL -1 When the concentration was 25 μg·mL, the levels of the three inflammatory factors were all reduced, among which the expression of IL-1β was most significantly reduced. Fr1-2 could significantly reduce the expression level of TNF-α at all three concentrations. -1 and 50 μg mL -1 When the concentration was 50 μg·mL -1 When , it had a very significant effect on the expression level of IL-6.

[0025] Therefore, the present invention also provides the use of the active components Fr1 and Fr1-2 of Lycium ruthenicum obtained by the above separation method in the preparation of anti-inflammatory products;

[0026] Furthermore, it is used in the preparation of products for reducing the expression of inflammatory factors TNF-α, IL-1β or IL-6;

[0027] Furthermore, it is used in the preparation of products for inhibiting the expression of COX-2 and p-IκBα / IκBα proteins;

[0028] Furthermore, the product is a medicine.

[0029] Lipopolysaccharide (LSP) is a chemical component unique to the outer wall of Gram-negative bacteria, and the pathogenicity of Gram-negative bacteria is usually related to the composition of their cell walls. In view of the fact that the active components Fr1 and Fr1-2 extracted by the method of the present invention have good anti-inflammatory activity. Therefore, the present invention also provides an application of the active components of Lycium barbarum obtained by the above separation method in the preparation of products that inhibit Gram-negative bacteria; the product is a medicine, specifically, the active components Fr1 and Fr1-2 of Lycium barbarum are used as effective ingredients, and various dosage forms of medicines are prepared according to any pharmaceutically acceptable carrier.

[0030] The beneficial effects of the present invention are:

[0031] The present invention studies the anti-inflammatory active components of black wolfberry other than anthocyanins, preliminarily clarifies the composition of the anti-inflammatory active components in black wolfberry fruit, and provides a basis for further studying its anti-inflammatory effect. At the same time, the present invention also provides a method for separating the anti-inflammatory active components of black wolfberry, which has the characteristics of simple operation and easy separation. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 MCI and macroporous resin preparative chromatograms of Lycium ruthenicum fruit extract;

[0033] Figure 2 Effects of different concentrations of LPS on RAW264.7 cell viability and NO release (*P<0.05, **P<0.01);

[0034] Figure 3 Effects of active components on RAW264.7 cell viability and NO release;

[0035] Figure 4 The effects of active components on the expression levels of inflammatory factors IL-6, IL1-β, and TNF-α in RAW264.7 cells;

[0036] Figure 5Effects of Fr1-2 on the expression of COX-2, p-IκBα, and IκBα proteins in RAW264.7 cells;

[0037] Figure 6 Fr1-2 preparation chromatogram;

[0038] Figure 7 Purity analysis and compound structure of compound 1. DETAILED DESCRIPTION

[0039] The technical solution of the present invention is described clearly and completely below in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0040] Materials and instruments

[0041] Lycium ruthenicum Murr., collected in Nomhong Farm, Qaidam Basin, Qinghai Province in 2021, was identified as Lycium ruthenicum by Gao Qingbo, a researcher at the Northwest Plateau Institute of Biology, Chinese Academy of Sciences; RAW264.7 mouse mononuclear macrophages (Cell Bank of Type Culture Collection Committee of Chinese Academy of Sciences); fetal bovine serum (BI, Kibbutz BeitHaemek, Israel); DMEM medium (Corning, New York USA); penicillin-streptomycin (Corning, NewYork USA); BCA protein detection kit (Solebao, Beijing, China); cell lysate (Solebao, Beijing, China); lipopolysaccharide LPS (Sigma-Aldrich Co, St. Louis MO USA); water (ultrapure water); methanol (analytical grade AR, Chengdu Kelong Chemical Co., Ltd.); dichloromethane (analytical grade AR, Chengdu Kelong Chemical Co., Ltd.); MCI (Mitsubishi Corporation of Japan); D101 macroporous resin (Cangzhou Baoen Adsorption Material Technology Co., Ltd.); Kromasil C18 column (4.6×250mm, 5μm); Kromasil C18 column (21.2×250mm, 5μm);

[0042] CO2 incubator (Memmert ICP500, Germany); microplate reader (BioTek Synergy Epoch 2, USA); HB-NP-7000C semi-preparative chromatography (Hanbang Technology Co., Ltd., China); Agilent high performance liquid chromatography (Agilent1260Infinity, USA); electrophoresis instrument (Tetra Cell, Bio-Rad, USA); electric heating blast drying oven (Shanghai Yiheng Scientific Instrument Co., Ltd., China)

[0043] Data processing: Western blot data were collected and processed using ImageJ software, and statistical analysis was performed using Graphpad prism8.0 statistical software. Data are expressed as mean ± standard deviation One-way ANOVA was used to compare the means of each group, and P < 0.05 was considered to be statistically significant.

[0044] Example 1 Extraction and separation of components from wolfberry fruit

[0045] 1) taking an alcohol extract of Lycium ruthenicum fruit and mixing it with polyamide powder;

[0046] The specific operation is as follows: 10.0 kg of dried black wolfberry fruit is extracted by immersion in methanol at room temperature and in the dark. The extraction conditions are: liquid-to-solid ratio is 20 mL g -1 , extract 3 times in total, each time for 4-5 days, filter the extract after each extraction, protect from light, reduce pressure and concentrate to obtain the alcohol extract of black wolfberry fruit. Add dry polyamide powder to the alcohol extract in a ratio of 1:1, mix the sample, dry it in an oven at 40℃, grind it, and pass it through a 20-mesh sieve.

[0047] 2) The mixed powder is separated by MCI open column chromatography to obtain components Fr1, Fr2, and Fr3 ( Figure 1 Left);

[0048] Take 50.00g of sieved powder, connect the medium pressure chromatographic column (49×460mm) equipped with MCI and the preparative liquid chromatography for dry loading. Use water A / methanol B / dichloromethane C three-phase system for elution, elution conditions: 0-120min, 100% A-100% B; 120-180min, 100% B-100% C; 120-180min, 100% B isocratic; 180-210min, 100% A isocratic. Flow rate: 50mL·min -1 , detection wavelength: 210nm, sample amount: 50.00g, a total of three components were obtained: Fr1 (12.6-39.7min), Fr2 (39.7-139.2min), and Fr3 (139.2-230.0min).

[0049] 3) The component Fr1 is separated by a macroporous resin column to obtain components Fr1-1 and Fr1-2 ( Figure 1 right);

[0050] The obtained component Fr1 was further separated. 30.0 g of Fr1 extract was taken and connected to a D101 macroporous resin column (49×460 mm) for further separation and preparation of Fr1 by semi-preparative chromatography. The chromatographic conditions were as follows: mobile phase: A: water, B: methanol, 0-30 min: 0% B; 30-90 min: 0-50% B; 90-120 min: 50% B, flow rate: 40 mL min -1 ; Detection wavelength: 210nm, 280nm, obtained components Fr1-1 (3.2-49.5min), Fr1-2 (49.5-120min).

[0051] In order to clarify the main material basis of component Fr1-2, 36.10 mg of Fr1-2 was taken, 3 mL of methanol was added to dissolve, and the main components of Fr1-2 were separated and prepared by semi-preparative chromatography using a C18 preparative column, and then identified. Chromatographic conditions: Mobile phase: A: water B: methanol. 0-30min: 5%-20% B, flow rate: 16 mL min -1 , detection wavelength: 280nm, compound 1 was obtained. The obtained compound was analyzed by HPLC, the conditions were: mobile phase A: water, mobile phase B: methanol. Elution conditions: 0-30min 5-20% B gradient elution, flow rate: 1mL·min -1 , column temperature 30℃, detection wavelength: 280nm.

[0052] Example 2 Separation and Analysis of the Main Components in Fr1-2

[0053] The main components in Fr1-2 were separated to obtain yellow oily compound 1 (t R =13.2min)( Figure 6 ). After analysis by C18 analytical column, the purity of compound 1 was 99.9% ( Figure 7 ). It was identified as 5-hydroxymethylfurfural by NMR and mass spectrometry data. Molecular formula: C6H6O3. EI-MS m / z(%): 126(M + ),109(M + -OH),97(M + -CHO), 1 HNMR ((CD3)2CO, 600MHz) δppm 2.91 (brs, alcohol OH), 4.63 (2H, s, CH2OH), 6.56 (1H, d, J = 3.5Hz, 4-H), 7.36 (1H, d, J = 3.5Hz, 3-H), 9.58 (1H, s, aldehyde H), 13CNMR ((CD3)2CO) ppm: 56.62 (CH2OH), 109.31 (C-4), 122.88 (C-3), 152.53 (C-2), 162.01 (C-1), 177.23 (aldehyde C), the above data are consistent with the MS, 1 HNMR, 13 The CNMR standard spectrum was consistent, so it was inferred to be 5-hydroxymethylfurfural (5-HMF).

[0054] Example 3 Study on the anti-inflammatory activity of Lycium ruthenicum extract

[0055] Inflammation can occur in multiple tissues and organs of the human body and is closely related to many diseases. Macrophages are special cells in the body that play an immune function and play an important physiological role in inflammation, tumors, and autoimmune regulatory systems. A large number of studies have shown that many inflammatory diseases of the body are closely related to macrophages. Lipopolysaccharide is a component of the outer membrane of Gram-negative bacteria and is widely used to establish an inflammatory model of macrophages. The present invention uses LPS to induce RAW264.7 cells to construct an inflammatory model.

[0056] 1) Establishment of LPS-induced RAW264.7 cell inflammation model

[0057] RAW264.7 cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (double antibody). The culture conditions were 37°C, 95% humidity, and 5% CO2 concentration. RAW264.7 macrophages were cultured at a density of 5×10 4 pc·mL -1 150 μL per well was inoculated into a 96-well plate and cultured in a cell culture incubator for 48 h. -1 , 1μg·mL -1 , 5μg·mL -1 , 10μg·mL -1 , 50μg·mL -1 , 100 μg·mL -1 and 200 μg mL -1 After 24 hours of induction with LPS, the cell viability was detected by MTT method, and the NO content in the cell supernatant was determined by NO kit to determine the optimal dose of LPS.

[0058] In order to screen out the appropriate modeling concentration, RAW264.7 cells were treated with different concentrations of LPS for 24 hours. The results showed that as the LPS concentration increased, the survival rate of RAW264.7 cells also decreased. The LPS concentration was 50-200 μg mL -1When the cell viability was significantly inhibited (P<0.01) ( Figure 2 ). When different concentrations of LPS were added, the NO release of cells increased significantly (P<0.01). -1 When NO release is the highest ( Figure 2 ), considering the two indicators, the present invention selects the LPS modeling concentration of 5 μmol·mL -1 .

[0059] 2) Study on the mechanism of anti-inflammatory active components of Lycium barbarum extract

[0060] Based on the established LPS-induced RAW264.7 cell inflammation model, the anti-inflammatory activity of the components of Lycium ruthenicum fruit extract was studied.

[0061] ① Experimental methods

[0062] The experiment was divided into a blank group, a model group, and three drug groups with low, medium, and high doses. The model group was treated with LPS, and the drug group was treated with LPS and 12.5, 25, and 50 μg mL -1 The components were treated at the same time and incubated together for 24 hours. The NO content in the culture medium was detected by NO kit, and the levels of inflammatory factors IL-6 and TNF-α were determined by ELISA kit.

[0063] The cells were 5×10 4 pc·mL -1 , 3mL·well -1 The cells were inoculated in 6-well plates and cultured under the same conditions as in 1). The experiment was divided into a blank group, an LPS group, and an LPS+drug group of different concentrations. The cells were treated after 24 hours of continuous culture. The cells were lysed and the total protein was extracted according to the instructions of the kit. The protein concentration was determined by the BCA method. The expression of COX-2 protein and IκBα protein and its phosphorylation level in the cells were detected by Western Blot. The protein was heated and denatured by adding Loading Buffer. The proteins were separated by 10% SDS-PAGE separation gel and 5% concentrated gel, transferred to the membrane, blocked with 5% skim milk for 1 hour, incubated with 1:1000 diluted rabbit primary antibodies COX-2, p-IκBα, IκBα, and β-actin at 4°C overnight, washed 3 times with TBST, and then incubated with 1:5000 diluted horseradish peroxidase-labeled secondary antibodies at room temperature for 1 hour. The cells were washed 3 times with TBST for development and photography. The protein bands were analyzed for grayscale using β-actin as an internal reference.

[0064] ②Effects of active components Fr1 and Fr1-2 on RAW264.7 cell viability, NO release and inflammatory factor expression levels

[0065] MTT method was used to detect the effects of anti-inflammatory active components Fr1 and Fr1-2 on RAW264.7 cell viability. Fr1-2 was detected at 100 μg·mL -1 , 200 μg·mL -1 When Fr1-2 was added, the survival rate of cells was increased. The concentrations of Fr1-2 did not significantly affect the viability of RAW264.7 cells ( Figure 3 ). According to the MTT results, 12.5, 25, and 50 μg mL -1 The subsequent experimental study was carried out at three concentrations. After LPS treatment, the amount of NO released by cells and the expression levels of various inflammatory factors increased significantly. When the action concentration was 25 μg mL -1 , 50μg·mL -1 When Fr1 and Fr1-2 were added, they could significantly inhibit the NO release in the LPS-induced RAW264.7 cell inflammatory model, and the inhibitory effect increased with the increase of concentration ( Figure 3 ). When the concentration of Fr1 is 25 μg·mL -1 The expression level of inflammatory factor TNF-α can be significantly reduced when the concentration is 50 μg·mL -1 When the concentration was 25 μg·mL, the levels of the three inflammatory factors were all reduced, among which the expression of IL-1β was most significantly reduced. Fr1-2 could significantly reduce the expression level of TNF-α at all three concentrations. -1 and 50 μg mL -1 When the concentration was 50 μg·mL -1 When , the expression level of IL-6 was significantly affected ( Figure 4 ). Compared with Fr-1, component Fr1-2 has a better inhibitory effect on the three inflammatory factors. Therefore, Fr1-2 was selected for further study of its mechanism of action.

[0066] ③Effects of the anti-inflammatory active component Fr1-2 on the expression of COX-2, p-IκBα and IκBα proteins in RAW264.7 cells

[0067] Because the Fr1-2 component has stronger anti-inflammatory activity, Western blot was used to detect the expression levels of COX-2, p-IκBα, and IκBα proteins in RAW264.7 cells to explore its anti-inflammatory mechanism. After LPS stimulation, the levels of COX-2 and p-IκBα / IκBα in RAW264.7 cells were upregulated, and the difference was statistically significant compared with the control group (P<0.05). The concentration of Fr1-2 component was 25 μg mL -1 and 50 μg mL -1When the concentration of Fr1-2 was increased, the expression of COX-2 protein was significantly inhibited, and the inhibitory effect became more obvious as the concentration increased. The three concentrations of Fr1-2 could inhibit the increase of p-IκBα / IκBα ratio, which was also dose-dependent ( Figure 5 The above research results indicate that Fr1-2 can play an anti-inflammatory role by reducing the release of NO in cells, reducing the levels of inflammatory factors IL-6, IL-1β and TNF-α, and inhibiting the expression of protein COX-2 and the phosphorylation of IκBα.

[0068] TNF-α, IL-1β, and IL-6 are the main inflammatory factors in the inflammatory response and are important indicators of the level of inflammation. Studies have shown that macrophages are activated after being stimulated by LPS, and the release of inflammatory mediators NO and inflammatory factors IL-6 is mediated through signal cascade pathways. The increase in IL-6 expression further promotes the secretion of NO. In addition, COX-2, as a key enzyme that converts arachidonic acid into prostaglandins (PGE2), can induce the production of a large number of prostaglandins (PGs), playing an important role in the inflammatory response. NF-κB is an inducible transcription factor that regulates the expression of a variety of inflammatory responses. Studies have shown that a variety of different inflammatory response target genes such as TNF-α and IL-6 can be activated by NF-κB, resulting in a large number of neutrophils infiltrating and gathering at the site of inflammatory response. IKB-α, as an NF-κB inhibitory protein, can reduce the activity of NF-κB by binding to it, making it inactivated. When IKB-α is phosphorylated and inactivated, NF-κB will be activated, enter the cell nucleus, bind to the nuclear response element, and regulate gene expression.

[0069] In summary, the present invention explores the anti-inflammatory effect of the black wolfberry fruit extract and its mechanism of action through the effects of the components of the black wolfberry fruit extract on the NO release in RAW264.7 cells, the expression of related inflammatory factors TNF-α, IL-1β, IL-6, protein COX-2 and IκBα. The results show that the components Fr1 and Fr1-2 obtained by extraction and separation have certain anti-inflammatory effects, and the component Fr1-2 shows better anti-inflammatory activity. In order to explore the material basis for the anti-inflammatory effect of the active component Fr1-2, the present invention further separates it, and obtains a yellow oily compound by separation and preparation, which is identified as 5-hydroxymethylfurfural. The present invention can provide certain data support and theoretical support for the separation and further development and utilization of the anti-inflammatory active components of the black wolfberry fruit.

Claims

1. A method for separating compound 1, It is characterized in that The structural formula of compound 1 is: , the separation method Includes the following: 1) Take the alcohol extract of Lycium barbarum fruit and mix it with polyamide powder; 2) Separating the mixed powders through an MCI open column to obtain components Fr1, Fr2, and Fr3; The method used was liquid chromatography, using a three-phase system of water A / methanol B / dichloromethane C as the eluent, and the elution conditions were: 0-120 min, 100% A-100% B; 120-180 min, 100% B-100% C; 120-180 min, 100% B isocratic; 180-210 min, 100% A isocratic; 3) Separating the component Fr1 through a macroporous resin column to obtain components Fr1-1 and Fr1-2; The separation column used was a D101 macroporous resin column, and the chromatographic conditions were as follows: mobile phase: A: water B: methanol, 0-30 min: 0% B; 30-90 min: 0-50% B; 90-120 min: 50% B; The component Fr1-2 was separated by liquid chromatography to obtain compound 1, wherein the mobile phase was: A: water, B: methanol; the chromatographic conditions were: 0-30 min, 5%-20% B.

2. The separation method according to claim 1, It is characterized in that The alcohol extract of wolfberry fruit refers to the concentrate obtained by extracting wolfberry with methanol, filtering it, and concentrating it in the dark.

3. The separation method according to claim 1, It is characterized in that Step 1) After the alcohol extract of Chinese wolfberry fruit is mixed with the polyamide powder, it needs to be dried, ground and sieved.

4. The separation method according to claim 1, It is characterized in that The flow rate of the HPLC in step 2) was 50 mL min -1 , the detection wavelength is 210 nm.

5. The separation method according to claim 1, It is characterized in that In step 3), the HPLC flow rate was 40 mL min -1 ; The detection wavelengths are 210 nm and 280 nm.

6. The separation method according to claim 1, It is characterized in that In step 3), the specification of the D101 macroporous resin column is 49×460 mm.

Citation Information

Patent Citations

  • Preparation methods of lycium ruthenicum anthocyanin extract and lyophilized powder and application in anti-gouty arthritis and uric acid reducing products

    CN113995798A

  • Lycium ruthenicum fruit extract as well as preparation method and application thereof

    CN103340983A

  • Application of lycium ruthenicum extract in preparing product for treating gout

    CN107375532A

  • Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising lycium barbarum extract

    KR1020180106105A